MAPT and Alzheimer disease: In addition, since PME-1, via inhibition of PP2A-B55 (the main tau phosphatase), has also been described to increase tau and APP phosphorylation in transgenic mice [7], direct PME-1 inhibition could have the additional benefit of preventing neurofibrillary tangle and Aβ plaque formation during AD pathogenesis.